HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Efficacy of novel nano-hydroxyapatite/polyurethane composite scaffolds with silver phosphate particles in chronic osteomyelitis.

Abstract
Recently, chronic osteomyelitis is still a challenging surgical problem. Unfortunately, the traditional clinical method using bone cement loaded antibiotics is restricted due to its non-biodegradability and limited release of antibiotics. Hydroxyapatite is a good adsorbent with good biocompatibility, an ideal bone repair material, and can avert the requirement for the secondary surgical procedure of removal. In this study, nano-hydroxyapatite combined with a polyurethane containing 3% silver (Ag/n-HA/PU) was synthesized, and investigated for its efficacy of treating chronic bone infection with bone defects. To clarify its silver ions release characteristics, the concentration of the Ag+ in the elution was analyzed every day after in vitro deionized water immersion. A chronic osteomyelitis of tibia in rabbit model was established, and 70 New Zealand rabbits were divided into 4 groups, including the blank control group, nano-hydroxyapatite combined with polyurethane (n-HA/PU) implant group, 3% Ag/n-HA/PU group and 10% Ag/n-HA/PU group after debridement. Routine blood tests, radiography, Micro-CT, and histological staining were conducted at 4 days, 3, 6 and 12 weeks post-treatment. The results showed that the released silver from the 3% Ag/n-HA/PU and 10% Ag/n-HA/PU exhibited an initial burst release and followed by a slow controlled release up to 39 days and 42 days respectively. A good repair of bone defects, an appropriate rate of degradation of scaffolds and no significant toxicity were observed in the 3% Ag/n-HA/PU group, indicating the advantages of this novel synthetic scaffold to be a potential option for the treatment of chronic osteomyelitis. A novel nano-composite, nano-hydroxyapatite combined with a polyurethane containing 3% silver (Ag/n-HA/PU) provide controlled release of Ag+, illustrated by its abilities of biodegradation, antimicrobial activity, and favorable repair of bone defects in the treatment of chronic osteomyelitis.
AuthorsDongli Zhang, Wen Liu, Xiang-Dong Wu, Xiaoqiang He, Xiao Lin, Han Wang, Jidong Li, Jiaxing Jiang, Wei Huang
JournalJournal of materials science. Materials in medicine (J Mater Sci Mater Med) Vol. 30 Issue 6 Pg. 59 (May 24 2019) ISSN: 1573-4838 [Electronic] United States
PMID31127361 (Publication Type: Journal Article)
Chemical References
  • Anti-Bacterial Agents
  • Biocompatible Materials
  • Bone Substitutes
  • Phosphates
  • Polyurethanes
  • Silver Compounds
  • Tolonium Chloride
  • Durapatite
  • silver phosphate
Topics
  • Adsorption
  • Animals
  • Anti-Bacterial Agents (administration & dosage)
  • Biocompatible Materials (chemistry)
  • Bone Regeneration (drug effects)
  • Bone Substitutes
  • Chronic Disease
  • Disease Models, Animal
  • Durapatite (chemistry)
  • Male
  • Nanoparticles (chemistry)
  • Osteomyelitis (therapy)
  • Phosphates (chemistry)
  • Polyurethanes (chemistry)
  • Rabbits
  • Silver Compounds (chemistry)
  • Staphylococcal Infections (drug therapy, prevention & control)
  • Staphylococcus aureus (drug effects)
  • Tibia (pathology)
  • Tissue Scaffolds
  • Tolonium Chloride
  • X-Ray Microtomography

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: